3-[2-fluoro-4-[4-[(1R)-1-hydroxyethyl]-1,3-oxazolidin-2-yl]-3-(trifluoromethoxy)phenyl]-3-[(1S)-1-[[4-[(4R)-4-[(1R)-1-hydroxyethyl]-2-oxo-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]-1,2,4-oxadiazolidin-5-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[2-fluoro-4-[4-[(1R)-1-hydroxyethyl]-1,3-oxazolidin-2-yl]-3-(trifluoromethoxy)phenyl]-3-[(1S)-1-[[4-[(4R)-4-[(1R)-1-hydroxyethyl]-2-oxo-1,3-oxazolidin-3-yl]pyrimidin-2-yl]amino]ethyl]-1,2,4-oxadiazolidin-5-one
• 化学式: C₂₅H₂₉F₄N₇O₈
• 分子量: 631.5
• InChiKey: OJYKDPQFUKWJSN-CUEKKERISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  44
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  189
• 氢给体数：
  6
• 氢受体数：
  17

文献信息

• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2014141104A1

  公开（公告）日：2014-09-18

  The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。
• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：Novartis AG

  公开号：EP2970240A1

  公开（公告）日：2016-01-20